• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Clinical Trial Listings
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • JobWatch
    • White Papers
    • Patient Education
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Trial Listings
  • Advertise
  • COVID-19
  • iConnect
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Actelion gets backing from shareholder

Actelion gets backing from shareholder

March 8, 2011
CenterWatch Staff

Swiss biotech group Actelion won the support of one of its biggest shareholders after Elliott Advisers called on Actelion to consider putting itself up for sale, according to FierceBiotech.

"Actelion has the right strategy in place to ensure sustained value creation," Rudolf Maag, who holds 4.2% of Actelion's outstanding shares, said in a statement.

"The company enjoys a strong, risk-balanced pipeline and invests the shareholders’ money in the right projects ... I am convinced that pursuing a stand-alone strategy where the benefits of these investments can be fully realized will maximize shareholder value over the medium to long term."

Maag is the first shareholder to come out in support of Actelion since largest shareholder Elliott made public letters to the board in which it urged Actelion to consider putting itself up for sale after a spate of product setbacks.

Elliott has called for Actelion's founder and Chief Executive Jean-Paul Clozel, as well as Chairman Robert Cawthorn, to resign from the board.

Elliott, which owns nearly 6% of the $7 billion company, is also using Georgeson, a firm of proxy solicitors, in a bid to gain more support among shareholders.

Upcoming Events

  • 15Apr

    Five Telltale Signs You’re Ready for an Electronic TMF System

  • 26Apr

    MAGI's Clinical Research vConference — Spring 2021

  • 06May

    The World of Post-COVID-19 Clinical Trials: How to Prepare for What’s Coming Next

Featured Products

  • Regenerative Medicine – Steps to Accelerate Development : PDF

    Regenerative Medicine: Steps to Accelerate Development

  • Clinical Trial Agreements — A Guide to Key Words and Phrases : PDF

    Clinical Trial Agreements: A Guide to Key Words and Phrases

Featured Stories

  • Clinical-Trial-Brainstorming

    FDA, Industry Tackle Problem of Including Older Adults in Trials

  • ClinicalTrialNetwork-360x240.png

    National Community-Based Research Network Would Improve Reach of Trials

  • Bottleneck-360x240.png

    Sites Face Trials Bottleneck After Pandemic, But Also Opportunities

  • AsktheExpertsBadge-360x240.png

    Ask the Experts: Genetic Research and IBC Oversight Requirements

Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

The information you need to adapt your monitoring plan to changing times.

Learn More Here
  • About Us
  • Contact Us
  • Privacy Policy
  • Do Not Sell My Personal Information

Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 617.948.5100 – Toll free 866.219.3440

Copyright © 2021. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing